Rapport Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Public

  • Employees
  • 84

Employees

  • Stock Symbol
  • RAPP

Stock Symbol

  • Share Price
  • $23.16
  • (As of Friday Closing)

Rapport Therapeutics General Information

Description

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Contact Information

Formerly Known As
Precision Neuroscience NewCo
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 99 High Street
  • Suite 2100
  • Boston, MA 02110
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 99 High Street
  • Suite 2100
  • Boston, MA 02110
  • United States
+1 (857)

Rapport Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rapport Therapeutics Stock Performance

As of 20-Nov-2026, Rapport Therapeutics’s stock price is $23.16. Its current market cap is $1.37B with 59.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.16 $23.58 $22.06 - $52.93 $1.37B 59.3M 781K -$3.18

Rapport Therapeutics Financials Summary

As of 30-Sep-2026, Rapport Therapeutics has a trailing 12-month revenue of $20M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,186,098 944,885 329,856
Revenue 20,000 0 0 0
EBITDA (166,714) (124,082) (89,606) (37,191)
Net Income (150,470) (111,483) (78,307) (34,786)
Total Assets 418,558 512,431 314,933 155,423
Total Debt 9,391 11,484 1,476 2,146
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rapport Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rapport Therapeutics‘s full profile, request access.

Request a free trial

Rapport Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Rapport Therapeutics‘s full profile, request access.

Request a free trial

Rapport Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-m
Drug Discovery
Boston, MA
84 As of 2025

Cambridge, MA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rapport Therapeutics Competitors (4)

One of Rapport Therapeutics’s 4 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Contineum Therapeutics Formerly VC-backed San Diego, CA
Coave Therapeutics Venture Capital-Backed Paris, France
Ashvattha Therapeutics Venture Capital-Backed Redwood City, CA
To view Rapport Therapeutics’s complete competitors history, request access »

Rapport Therapeutics Patents

Rapport Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165047-A1 Nicotinic acetylcholine receptor modulators and uses therein Pending 29-Jan-2025
WO-2025231416-A1 Methods of use of ampa receptor modulators Pending 03-May-2024
AU-2025209427-A1 Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy Pending 17-Jan-2024
WO-2025155830-A1 Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy Inactive 17-Jan-2024
US-10100045-B2 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators Active 26-Oct-2016 C07D417/14
To view Rapport Therapeutics’s complete patent history, request access »

Rapport Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rapport Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Rapport Therapeutics‘s full profile, request access.

Request a free trial

Rapport Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.18 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Rapport Therapeutics’s complete esg history, request access »

Rapport Therapeutics FAQs

  • When was Rapport Therapeutics founded?

    Rapport Therapeutics was founded in 2022.

  • Where is Rapport Therapeutics headquartered?

    Rapport Therapeutics is headquartered in Boston, MA.

  • What is the size of Rapport Therapeutics?

    Rapport Therapeutics has 84 total employees.

  • What industry is Rapport Therapeutics in?

    Rapport Therapeutics’s primary industry is Drug Discovery.

  • Is Rapport Therapeutics a private or public company?

    Rapport Therapeutics is a Public company.

  • What is Rapport Therapeutics’s stock symbol?

    The ticker symbol for Rapport Therapeutics is RAPP.

  • What is the current stock price of Rapport Therapeutics?

    As of 20-Nov-2026 the stock price of Rapport Therapeutics is $23.16.

  • What is the current market cap of Rapport Therapeutics?

    The current market capitalization of Rapport Therapeutics is $1.37B.

  • What is Rapport Therapeutics’s current revenue?

    The trailing twelve month revenue for Rapport Therapeutics is $20M.

  • Who are Rapport Therapeutics’s competitors?

    Sarepta Therapeutics, Contineum Therapeutics, Coave Therapeutics, and Ashvattha Therapeutics are competitors of Rapport Therapeutics.

  • What is Rapport Therapeutics’s annual earnings per share (EPS)?

    Rapport Therapeutics’s EPS for 12 months was -$3.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process